The US tariff that was imposed on Chinese goods in the name of fentanyl ended in February 2026, when the Supreme Court ruled that emergency powers do not authorise tariffs. China's side of that bargain has continued. Beijing has added to its export controls on fentanyl ingredients twice since then, most recently on 22 September 2026, and both governments report joint police cases. Washington's own documents record the steps and say they are not yet enough.1 2 3
What the two sides traded in 2025
The tariff dates from an executive order of 1 February 2025 that added 10% to duties on Chinese products under the International Emergency Economic Powers Act, as part of a declared emergency over drug trafficking. After the Busan meeting of the two presidents, the White House said China had agreed to "stop the shipment of certain designated chemicals to North America", and the United States lowered the tariff by 10 percentage points from 10 November 2025.3 4
China's part followed that month. Five agencies led by the Commerce Ministry placed 13 fentanyl precursors, the chemicals from which the drug is made, under export licensing for three destinations: the United States, Mexico and Canada. The Congressional Research Service, which advises the US Congress, describes this as the first time China had controlled such exports to North America.3 5
Two additions in 2026
Three more precursors were added for the same three countries in May 2026, around the first of this year's meetings between Donald Trump and Xi Jinping.5 3
On 22 September 2026, shortly before the two presidents met in Washington, the five agencies added two more, the methyl and ethyl forms of one piperidine compound, with effect from the day of publication.1 3
向美国、墨西哥、加拿大出口附件1第一部分所列化学品的,应按照《向特定国家(地区)出口易制毒化学品暂行管理规定》申请许可。
Exports to the United States, Mexico and Canada of the chemicals listed in part one of annex 1 require a licence under the interim rules on exporting precursor chemicals to specific countries and regions.1
Adding the three notices together gives 18 chemicals. The notice says exports of them to other countries and regions need no licence under these rules.1 5
The tariff that these controls were first exchanged for no longer exists. The Supreme Court invalidated the emergency-powers tariffs in February 2026. China has not withdrawn the controls, and both additions of 2026 came around meetings of the two presidents.3
What Beijing says it has done
China's account was set out at a press conference on 17 June 2026 by Wei Xiaojun, executive deputy head of the National Narcotics Control Commission. He described regular contact with the White House drug policy office, joint cases with the US Drug Enforcement Administration, the FBI and Homeland Security Investigations, and the return of fugitives. He also listed tighter customs checks on the listed chemicals and identity and X-ray rules for parcels.5
通过合作,还根据美方提供的信息和线索侦办了一些案件。
Through this cooperation we have also investigated a number of cases on the basis of information and leads supplied by the US side.5
Xinhua, China's state news agency, reported one such case on 10 September 2026. Acting on information that US authorities passed on in May, in a case handled with the FBI, police in Hebei province and elsewhere arrested 21 suspects in August and seized precursor chemicals. US authorities arrested two Americans in the same case. Xinhua quoted a scholar at the People's Public Security University of China as saying the cooperation showed China's commitment to helping the United States with its fentanyl crisis.6
Beijing's standing position, as the Congressional Research Service summarises it, is that American demand is the core of the problem and that the tariffs "dealt a heavy blow" to cooperation on drugs.3
What Washington says
The White House fact sheet of 25 September 2026 acknowledged the same events and asked for more. It welcomed China's scheduling of orphines, which it called a class of deadly drugs, and "noted" the two new export controls, while "strongly encouraging the permanent scheduling of these and other substances and chemicals". Scheduling means placing a substance under drug-control law, which goes further than an export licence for three countries. On the 21 arrests, it said the United States "strongly encouraged maximum sentences, including the death penalty where applicable".2
Other US documents are more critical. The State Department's 2025 narcotics report, quoted by the Congressional Research Service, said China's enforcement "remains uneven and opaque". The US intelligence agencies' threat assessment of March 2026 named China and India as the main sources of fentanyl precursors and pill presses. In December 2025 an executive order designated illicit fentanyl and its core precursors as weapons of mass destruction.3
The same report records movement in the other direction. The Drug Enforcement Administration has assessed that some Chinese chemical firms may now be unwilling to supply controlled precursors abroad. The Centers for Disease Control and Prevention estimate about 37,393 US deaths from synthetic opioids in 2025, about 52% below the peak of 77,695 in the twelve months to June 2023. The report does not attribute that fall to any single cause.3
What is still open
Fentanyl does not appear in the Chinese Commerce Ministry's ten-point account of the September trade talks, which extended the truce to 10 January 2027. The precursor notice of 22 September 2026 states no expiry date, unlike the truce measures.7 1
The open question is whether China moves from export licences for North America to permanent domestic scheduling, as Washington asks. The Congressional Research Service notes that Congress may also examine how the weapons of mass destruction designation affects cooperation with China. No date has been announced for either.2 3